Medical Research for Our Troops Act

The 'Medical Research for Our Troops Act' (HR3906) was introduced in the House on June 11, 2025, by Rep. Carson (D-IN-7) and 48 cosponsors. The bill aims to amend the Full-Year Continuing Appropriations and Extensions Act, 2025, to restore $1,181,612,000 to the Defense Health Agency for research, development, test, and evaluation, including Congressionally Directed Medical Research Programs. It was referred to the House Committee on Appropriations on the same day. The bill specifies that the restored funds would be implemented in levels and a manner consistent with the Consolidated Appropriations Act, 2024, ensuring support for all research programs, peer-reviewed initiatives, and projects identified in the explanatory statement accompanying that act. The Secretary of Defense would be directed to obligate and expend these funds to preserve program continuity, including adherence to specified funding allocations and research priorities. This represents an authorization to restore funds, and actual appropriation would depend on the bill's passage and subsequent funding decisions. Structural winners, should this bill pass and the funds be appropriated, include companies involved in medical research, device manufacturing, and pharmaceuticals that contract with the Defense Health Agency. This includes major players like Johnson & Johnson ($JNJ), Pfizer Inc. ($PFE), Merck & Co., Inc. ($MRK), Medtronic plc ($MDT), and Stryker Corporation ($SYK), which have established defense contracting relationships or are positioned to engage in military health R&D. The bill specifically targets the restoration of funds, indicating a potential increase in available contract opportunities for these types of companies. Looking at recent market data, Johnson & Johnson ($JNJ) is currently at $239.36, showing a -2.08% change over the last 7 days and -0.44% over 30 days. Pfizer Inc. ($PFE) is at $27, with a -3.85% change over 7 days and -0.18% over 30 days. Merck & Co., Inc. ($MRK) is at $118.33, with a -1.63% change over 7 days but a +2.19% change over 30 days. Medtronic plc ($MDT) is at $86.44, showing a -0.24% change over 7 days and -4.91% over 30 days. Stryker Corporation ($SYK) is at $331.49, with a +0.88% change over 7 days but a -9.07% change over 30 days. The bill is in its early stages, having only been referred to committee, meaning significant legislative steps remain before any funding restoration could occur. For this bill to progress, it must be considered and approved by the House Committee on Appropriations, then pass a vote in the full House. Following House passage, it would need to go through a similar process in the Senate and ultimately be signed into law by the President. Given its early stage, the timeline for potential enactment is uncertain.